Celgene Corporation - Recruiting 18 years or older. - A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
Merrimack Pharmaceuticals - Recruiting 12 Months to 20 years. - Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors.
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
University College, London - Recruiting 5 years to 50 years. - A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma.
St. Jude Children's Research Hospital - Recruiting 6 years to 30 years. - A Pilot Study on the Effects of Preoperative Physical Therapy in Adolescents and Young Adults Diagnosed With a Lower Extremity Malignancy.
Endurance; Strengthening; Stretching; Home exercise program
The Hospital for Sick Children - Recruiting 6 years to 18 years. - Assessing the Safety, Feasibility, Cost Effectiveness and Patient Satisfaction of Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma.
Centre Leon Berard - Recruiting 1 year to 50 years. - Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma.